24 Jun 2009
Rumours that Apple chief executive Steve Jobs received a liver transplant two months ago have been confirmed by the Methodist University Hospital Transplant Institute in Tennessee.
The hospital addressed speculation that Jobs had been given preferential treatment over other patients on the waiting list.
"He received a liver transplant because he was the patient with the highest Model for End-Stage Liver Disease score of his blood type, and therefore the sickest patient on the waiting list at the time a donor organ became available, " said the hospital in a statement. "Mr Jobs is now recovering well and has an excellent prognosis."
Several reports claim that Jobs has already returned to work at Apple, although the company has not yet confirmed whether this is the case.
Jobs's health has been a subject of deep concern for Apple enthusiasts and shareholders. His gaunt appearance at last year's Worldwide Developers Conference led to a statement of reassurance from Apple in January that Jobs was not suffering from a resurgence of pancreatic cancer.
Jobs said at the time that he was suffering from a hormone imbalance, and would take a six-month leave of absence from the company.
Rumours that Jobs had undergone a liver transplant emerged earlier this week.
Latest stories from Management
Related articles
Related jobs
Poll
What is the most important IT priority for your company this year?
Connect with V3.co.uk
This paper focuses on a series of best practices and techniques for development teams looking to improve their software development processes
Why good data management at all levels is essential in the modern business (video, 6mins)
Overview: My client; Based in the City...
**New Vacancy** Based in London Up to £35,000 - £42...
Junior BA The role of the junior BA is to support the...
Project Manager - Financial Services IT - up to £85'000...
Keep up to date with the latest products, services and technologies from the world's leading IT companies. IThound.com brings you over 2,000 white papers, case studies and analyst reports.
Do you agree?